RT Journal Article SR Electronic T1 Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease JF Cleveland Clinic Journal of Medicine JO Cleve Clin J Med FD Cleveland Clinic SP 317 OP 323 VO 62 IS 5 A2 Donald G. Vidt A1 Aaron Brzezinski A1 George B. Rankin A1 Douglas L. Seidner A1 Bret A. Lashner YR 1995 UL http://www.ccjm.org/content/62/5/317.abstract AB SUMMARY Although sulfasalazine, a 5-aminosalicylic acid (5-ASA) agent, is still the anti-inflammatory agent of choice for ulcerative colitis and Crohn's disease, newer formulations, which release drug to specific regions of the colon for maximal efficacy, also can be appropriate first-line agents. This article reviews recent clinical studies of therapy with older and newer 5-ASA formulations.